Clinical Trial

Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn how people's different genetic makeups affects how their bodies convert the FDA approved drug ARAKODA (tafenoquine) to its active form. Tafenoquine is a drug that is taken to prevent malaria for people traveling to areas where there is malaria. This trial will be in healthy participants age 18-65.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-23.
Trial Details
NCT Number NCT07373743
Lead Sponsor State University of New York - Upstate Medical University
Conditions Pharmacokinetic in Normal Population
Enrollment 20 participants
Start Date 2026-05
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-20